Northern Trust
KLRS

Northern Trust’s Kalaris Therapeutics KLRS Stock Holding History

Northern Trust’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.4K Buy
14,449
+795
+6% +$7.06K ﹤0.01% 4145
2025
Q4 		$115K Buy
+13,654
New +$87.3K ﹤0.01% 4113
2025
Q1 		– Sell
-6,943
Closed -$67.1K – 4512
2024
Q4 		$67.1K Buy
6,943
+55
+0.8% +$832 ﹤0.01% 4223
2024
Q3 		$128K Sell
6,888
-12,126
-64% -$212K ﹤0.01% 3998
2024
Q2 		$316K Sell
19,014
-528
-3% -$9.32K ﹤0.01% 3678
2024
Q1 		$339K Buy
19,542
+882
+5% +$14.4K ﹤0.01% 3701
2023
Q4 		$292K Sell
18,660
-2,027
-10% -$79.9K ﹤0.01% 3736
2023
Q3 		$1.02M Sell
20,687
-1,711
-8% -$117K ﹤0.01% 3287
2023
Q2 		$1.75M Buy
22,398
+3,041
+16% +$289K ﹤0.01% 3081
2023
Q1 		$1.75M Sell
19,357
-636
-3% -$81K ﹤0.01% 2993
2022
Q4 		$2.36M Buy
19,993
+209
+1% +$35.4K ﹤0.01% 2912
2022
Q3 		$3.59M Buy
19,784
+7,630
+63% +$1.19M ﹤0.01% 2687
2022
Q2 		$1.09M Sell
12,154
-216
-2% -$22.6K ﹤0.01% 3324
2022
Q1 		$1.92M Sell
12,370
-590
-5% -$118K ﹤0.01% 3124
2021
Q4 		$3.86M Buy
12,960
+121
+0.9% +$56.1K ﹤0.01% 2850
2021
Q3 		$7.4M Buy
12,839
+236
+2% +$109K ﹤0.01% 2487
2021
Q2 		$5.72M Sell
12,603
-75
-0.6% -$38.7K ﹤0.01% 2761
2021
Q1 		$6.82M Buy
12,678
+3,410
+37% +$2.87M ﹤0.01% 2543
2020
Q4 		$8.19M Sell
9,268
-25
-0.3% -$19.2K ﹤0.01% 2380
2020
Q3 		$5.88M Buy
+9,293
New +$6.35M ﹤0.01% 2425

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Northern Trust's KLRS Position: Q1 2026 in Review

Northern Trust increased its Kalaris Therapeutics (KLRS) stake by 5.8% in Q1 2026, buying an estimated $7.06K and bringing the position to 14,449 shares worth $83.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4145.

Northern Trust first reported a position in KLRS in Q3 2020 and has held it in 20 quarters since. The position peaked at $8.19M in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Northern Trust held 14,449 shares of Kalaris Therapeutics worth $83.4K as of Q1 2026.
  • Northern Trust bought 795 Kalaris Therapeutics shares in Q1 2026, an estimated $7.06K.
  • Kalaris Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4145 holding.
  • Northern Trust first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • Northern Trust's Kalaris Therapeutics position peaked at $8.19M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.